B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: The VITAmins to prevent stroke (VITATOPS) MRI-substudy

Stroke

Volumn 43, Issue 12, 2012, Pages 3266-3270

  Cavalieri, Margherita ^a   Schmidt, Reinhold ^a   Chen, Christopher ^b   Mok, Vincent ^c   De Freitas, Gabriel R ^d   Song, Swithin ^e   Yi, Qilong ^f   Ropele, Stefan ^a   Grazer, Anja ^a   Homayoon, Nina ^a   Enzinger, Christian ^a   Loh, Katherine ^e   Wong, Ka Sing Lawrence ^c   Wong, Adrian ^c,g   Xiong, Yunyun ^c,h   Chang, Hui Meng ⁱ   Wong, Meng Cheong ^b   Fazekas, Franz ^a   Eikelboom, John W ^j   Hankey, Graeme J ^k  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e ROYAL PERTH HOSPITAL   (Australia)

^f UNIVERSITY OF OTTAWA   (Canada)

^g THE EDUCATION UNIVERSITY OF HONG KONG   (Hong Kong)

^h MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

ⁱ NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^j MCMASTER UNIVERSITY   (Canada)

^k NONE

more..

Author keywords

Cerebral small vessel diseases; Folic acid; Homocysteine; Randomized controlled trial; Stroke; Vitamin B deficiency

Indexed keywords

PLACEBO; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPOTHESIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRANSIENT ISCHEMIC ATTACK; VITAMIN SUPPLEMENTATION; WHITE MATTER;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LEUKOENCEPHALOPATHIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLACEBOS; STROKE, LACUNAR; TREATMENT FAILURE; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 84870882890     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.665703     Document Type: Article

References (24)

1. Fassbender K, Mielke O, Bertsch T, Nafe B, Fröschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 1999;353:1586-1587.
2. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 2000;31:1069-1075.
3. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127(pt 1):212-219.
4. Seshadri S, Wolf PA. Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol. 2003;2:11.
5. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82: 806-812.
6. The VITATOPS Trial Study Group. The VITATOPS (VITAmins To Prevent Stroke) trial: Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis. 2002;13:120-126.
7. The VITATOPS Trial Study Group. The VITAmins TO Prevent Stroke (VITATOPS) trial: Rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke. 2007;2:144-150.
8. Fazekas F, Niederkorn K, Schmidt R, Offenbacher H, Horner S, Bertha G, Lechner H. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke. 1988;19: 1285-1288.
9. Kapeller P, Barber R, Vermeulen RJ, Adèr H, Scheltens P, Freidl W, Almkvist O, Moretti M, del Ser T, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F; European Task Force of Age Related White Matter Changes. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003;34:441-445.
10. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F; Austrian Stroke Prevention Study. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet. 2003;361:2046-2048.
11. Plummer D. DispImage: a display and analysis tool for medical images. Revista di Neuroradiologica. 1992;5:489-495
12. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol. 2002;51:285-289.
13. Dufouil C, Alpérovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol. 2003;53:214-221.
14. The VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010;9:855-65.
15. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol. 2002;59:787-793.
16. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull. 1999;55:669-682.
17. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 1997;94:5923-5928.
18. Wolf R, Schabitz FL, Fisher M, Pak HC. The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke. 2003;31:1709-1714
19. Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, et al. Acute Antiplatelet Stroke Trialists Collaboration Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2010:43:1058-1066.
20. th century. Lancet Neurol. 2003;2:43-53.
21. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Progression of leukoaraiosis and cognition. Stroke. 2007;38:2619-2625.
22. Vermeulen EG, Stehouwer CD, Valk J, van der Knaap M, van den Berg M, Twisk JW, Prevoo W, Rauwerda JA. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial. Eur J Clin Invest. 2004;34:256-261.
23. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O'Brien J, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A, Pantoni L; LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ. 2009;339:b2477.
24. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41:600-606.